Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 81

Results For "revenue"

852 News Found

RPG Life Sciences Q1FY22 PAT surges to Rs. 13.58 Cr
News | July 29, 2021

RPG Life Sciences Q1FY22 PAT surges to Rs. 13.58 Cr

The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.


Sun Pharma signs Cassiopea for license and supply agreements
News | July 27, 2021

Sun Pharma signs Cassiopea for license and supply agreements

Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older


Glenmark Life Sciences IPO to open on July 27, 2021
News | July 26, 2021

Glenmark Life Sciences IPO to open on July 27, 2021

The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration


Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr
News | July 22, 2021

Gland Pharma Q1FY22 consolidated PAT rises to Rs. 350.65 Cr

The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.


Jubilant Pharmova’s Roorkee facility placed under import alert
News | July 16, 2021

Jubilant Pharmova’s Roorkee facility placed under import alert

The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.


Sun Pharma settles patent litigation for Revlimid
News | June 23, 2021

Sun Pharma settles patent litigation for Revlimid

Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules


JB Chemicals PAT jumps by 101% to Rs101 Cr
News | June 15, 2021

JB Chemicals PAT jumps by 101% to Rs101 Cr

The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020


Lupin receives warning letter from U.S. FDA
News | June 14, 2021

Lupin receives warning letter from U.S. FDA

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility


Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
News | June 14, 2021

Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years

The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination


'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.
Interviews | June 10, 2021

'We plan to invest Rs. 1,000 Cr in the next 3 to 4 years.' Priyanka Chigurupati, Executive Director, Granules Pharmaceutical Inc.

In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview: